Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients

Sponsor
Power Life Sciences Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05728125
Collaborator
(none)
500
24

Study Details

Study Description

Brief Summary

Historically, clinical study participation has been biased toward certain demographics. However, there is a shortage of studies that delve into the underlying factors that influence patient participation, both positively and negatively.

Several people will be invited to enroll in this study so that it may collect a variety of data about glioblastoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.

The data collected from this study will be analyzed and used to improve the experiences of future glioblastoma patients who are recruited for medical trials.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    An In Depth Study Evaluating The Experiences of Patients In Glioblastoma Clinical Trials
    Anticipated Study Start Date :
    Mar 3, 2023
    Anticipated Primary Completion Date :
    Mar 3, 2024
    Anticipated Study Completion Date :
    Mar 3, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients who decide to participate in a glioblastoma clinical trial [3 months]

    2. Rate of patients who remain in glioblastoma clinical trial to trial completion [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient has self-identified as planning to enroll in a clinical trial

    • Patient has been diagnosed with glioblastoma

    • Patient is a minimum of 18 years or older

    Exclusion Criteria:
    • Patient does not understand, sign, and return consent form

    • Inability to perform regular electronic reporting

    • Patient is pregnant

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Power Life Sciences Inc.

    Investigators

    • Study Director: Michael B Gill, Power Life Sciences Inc.

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    Power Life Sciences Inc.
    ClinicalTrials.gov Identifier:
    NCT05728125
    Other Study ID Numbers:
    • 82966461
    First Posted:
    Feb 14, 2023
    Last Update Posted:
    Feb 14, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Power Life Sciences Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 14, 2023